US President Donald Trump announced “Big Zölle” on Tuesday at pharmaceutical imports (local time). These are intended to create companies for companies to move their activities to the United States. Medicines may not be included in the new rates.
However, experts do not consider it realistic that the pharmaceutical industry is now switching to move its production to the United States. “If the United States actually increases Pharmacölle, companies with the lowest gross margins (…) can have the biggest negative effects on winning, although there are numerous reservations,” reported the Bloomberg News Company.
Shares fall again
In the industrial comparison, the stock markets already had the strongest discounts on pharmaceutical values on Wednesday. The Sanofi articles of the pharmaceutical and medical company with the same name bent by 6.3 percent. Novo Nordisk, Roche and Novartis lost between 5.4 and seven percent in the middle of the week.
In short, the pharmaceutical sector is considered rather stable. It was recently said that the pharmaceutical was probably spared afterwards. Trump had proposed in February to increase 24 percent rates on medicinal products. Ireland, Denmark, Belgium and Germany include the EU countries that are most affected by pharmaceutical tasks. American companies such as Pfizer and Johnson & Johnson have production facilities.
Dependence created itself
In the previous year, medicines with a value of 117 billion euros were the most important American importer of the EU. The current dependence on the United States of pharmaceutical exports and active substances of the EU is partly the product of Trump’s own policy in 2017.
Deep in the minus, oil and real estate values were also mentioned on Wednesday. Bank shares also went far down on Wednesday. An industrial view in Europe clearly showed all sectors in the loss zone. In Vienna, the OMV share fell three percent lower. In the middle of the week, oil prices have fallen to the lowest level since 2021.
Source: Krone
I’m Ben Stock, a journalist and author at Today Times Live. I specialize in economic news and have been working in the news industry for over five years. My experience spans from local journalism to international business reporting. In my career I’ve had the opportunity to interview some of the world’s leading economists and financial experts, giving me an insight into global trends that is unique among journalists.
